IMA
NASDAQ · Pharmaceuticals
Imagenebio Inc
$5.77
+0.06 (+1.05%)
Financial Highlights (FY 2026)
Revenue
1.83M
Net Income
-103,554,998
Gross Margin
—
Profit Margin
-5,668.6%
Rev Growth
-62.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 31.5% | 31.5% |
| Operating Margin | -6,056.4% | -5,450.7% | 13.4% | 16.1% |
| Profit Margin | -5,668.6% | -5,385.2% | 10.3% | 13.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.83M | 4.92M | 44.29M | 39.41M |
| Gross Profit | — | — | 13.97M | 12.43M |
| Operating Income | -110,610,816 | -268,039,134 | 5.94M | 6.35M |
| Net Income | -103,554,998 | -250,941,029 | 4.55M | 5.11M |
| Gross Margin | — | — | 31.5% | 31.5% |
| Operating Margin | -6,056.4% | -5,450.7% | 13.4% | 16.1% |
| Profit Margin | -5,668.6% | -5,385.2% | 10.3% | 13.0% |
| Rev Growth | -62.9% | -62.9% | -0.9% | +2.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 19.74M | 17.02M |
| Total Equity | — | — | 39.52M | 44.51M |
| D/E Ratio | — | — | 0.50 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -109,727,011 | -280,669,521 | 9.89M | 9.22M |
| Free Cash Flow | — | — | 3.33M | 3.29M |